---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002719"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:20:06.871281+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Treace Medical reports preliminary Q4 2023 revenue ~$62M, full-year ~$187M above guidance

## Summary
- Preliminary Q4 revenue $61.8M–$62.2M, ~25% YoY increase; full-year revenue $186.7M–$187.1M, ~32% increase and above guidance of $182M–$186M.
- Blended avg. revenue per Lapiplasty kit in Q4 was $6,437, a record high and 9% increase over Q4 2022.
- Added ~164 new active surgeons in Q4 and ~468 for full year; total active surgeons ~2,855, up 20% YoY.
- Direct sales reps at 227, up 35% over end of 2022; direct channel contributed 82% of Q4 revenue.
- 2024 financial guidance to be provided on the Feb 27, 2024 earnings call.

## SEC filing metadata
- accession: 0000950170-24-002719
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000095017024002719/0000950170-24-002719-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000095017024002719/tmci-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002719
- JSON: https://secwatch.observer/filing/0000950170-24-002719.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002719.txt

## Key facts
- Earnings Releases
  TREACE MEDICAL CONCEPTS, INC. reported the fourth quarter of 2023 results: revenue $61.8 million to $62.2 million.
  - Period: the fourth quarter of 2023
  - Revenue: $61.8 million to $62.2 million
  - Result: preliminary results
  source text: Preliminary revenue of $61.8 million to $62.2 million in the fourth quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1630627/000095017024002719/0000950170-24-002719-index.htm
- Earnings Releases
  TREACE MEDICAL CONCEPTS, INC. reported the full-year 2023 results: revenue $186.7 million to $187.1 million.
  - Period: the full-year 2023
  - Revenue: $186.7 million to $187.1 million
  - Result: preliminary results
  source text: Preliminary revenue of $186.7 million to $187.1 million for the full-year 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1630627/000095017024002719/0000950170-24-002719-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.